Research from Martin-Luther University provides new data about coagulation therapy

Scientists discuss in "Recombinant factor VIIa reduces bleeding risk in patients on platelet aggregation inhibitors immediately prior to renal transplantation--a retrospective analysis" new findings in coagulation. According to a study from Halle, Germany, "Transplant surgery often requires an effective preoperative treatment which allows to reduce the risk of bleeding caused by platelet aggregation inhibitors without major delay. The use of recombinant activated coagulation factor VIIa (rFVIIa) may be a future treatment option in such patients. Five patients with end-stage renal disease on treatment with platelet aggregation inhibitors (ASA, Plavix, Aggrenox), who were scheduled for renal...

Want to see the full article?

• Purchase this article for only $3.00